WallStreetZenWallStreetZen

NASDAQ: BCEL
Atreca Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BCEL

Based on 2 analysts offering 12 month price targets for Atreca Inc.
Min Forecast
$1.00+314.94%
Avg Forecast
$1.00+314.94%
Max Forecast
$1.00+314.94%

Should I buy or sell BCEL stock?

Based on 2 analysts offering ratings for Atreca Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BCEL stock forecasts and price targets.

BCEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-08-14
lockedlocked$00.00+00.00%2023-08-11

1 of 1

Forecast return on equity

Is BCEL forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.36%

Forecast return on assets

Is BCEL forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

BCEL revenue forecast

What is BCEL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$50.0M
Avg 2 year Forecast
$50.0M
Avg 3 year Forecast
$50.0M

BCEL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCEL$0.24$1.00+314.94%Hold
ARAV$0.13$0.25+92.31%Hold
PSTV$2.12$8.00+277.36%Buy
TNXP$0.40$8.00+1,910.05%Strong Buy
GOVX$0.36$8.00+2,122.22%Buy
View Top Biotech Stocks

Atreca Stock Forecast FAQ

Is Atreca Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BCEL) stock is to Hold BCEL stock.

Out of 2 analysts, 0 (0%) are recommending BCEL as a Strong Buy, 0 (0%) are recommending BCEL as a Buy, 2 (100%) are recommending BCEL as a Hold, 0 (0%) are recommending BCEL as a Sell, and 0 (0%) are recommending BCEL as a Strong Sell.

If you're new to stock investing, here's how to buy Atreca stock.

What is BCEL's revenue growth forecast for 2024-2027?

(NASDAQ: BCEL) Atreca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.

Atreca's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast BCEL's revenue for 2024 to be $1,981,203,750, with the lowest BCEL revenue forecast at $1,981,203,750, and the highest BCEL revenue forecast at $1,981,203,750. On average, 1 Wall Street analysts forecast BCEL's revenue for 2025 to be $1,981,203,750, with the lowest BCEL revenue forecast at $1,981,203,750, and the highest BCEL revenue forecast at $1,981,203,750.

In 2027, BCEL is forecast to generate $1,981,203,750 in revenue, with the lowest revenue forecast at $1,981,203,750 and the highest revenue forecast at $1,981,203,750.

What is BCEL's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: BCEL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is BCEL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BCEL price target, the average BCEL price target is $1.00, with the highest BCEL stock price forecast at $1.00 and the lowest BCEL stock price forecast at $1.00.

On average, Wall Street analysts predict that Atreca's share price could reach $1.00 by Aug 14, 2024. The average Atreca stock price prediction forecasts a potential upside of 314.94% from the current BCEL share price of $0.24.

What is BCEL's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: BCEL) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.